Pre-clinical Study of ²¹³Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic Cancer

Author： Qu Chang Song Emma Li Yong Rizvi Syed Raja Chand Smith Ross Morgenstern Alfred Apostolidis C. Allen Barry

ISSN： 0262-0898

Source： Clinical and Experimental Metastasis, Vol.22, Iss.7, 2005-11, pp. : 575-586

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

In Vitro Cytotoxicity of Bismuth-213 (^213bi)-Labeled-Plasminogen Activator Inhibitor Type 2 (Alpha-PAI-2) on Human Breast Cancer Cells

By Ranson M.

Breast Cancer Research and Treatment, Vol. 71, Iss. 2, 2002-01 ,pp. : 149-159

Springer Publishing Company

Access to resources Recommend Favorite

Targeting Aberrant TGF-&bgr; Signaling in Pre-Clinical Models of Cancer

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 7, Iss. 5, 2007-01 ,pp. : 504-514

Bentham Science Publishers

Access to resources Recommend Favorite

Continuous administration of recombinant human endostatin (Endostar): A pre-clinical safety study

Experimental and Therapeutic Medicine, Vol. 3, Iss. 6, 2012-01 ,pp. : 1018-1022

Spandidos Publications

Access to resources Recommend Favorite

Statins and pancreatic cancer risk: a nested case–control study

By Bradley Marie

Cancer Causes and Control, Vol. 21, Iss. 12, 2010-12 ,pp. : 2093-2100

Springer Publishing Company

Access to resources Recommend Favorite

Breast Cancer Outcomes and Micrometastatic Disease

By Giuliano Armando

Annals of Surgical Oncology, Vol. 15, Iss. 4, 2008-04 ,pp. : 1258-1258

Springer Publishing Company

Access to resources Recommend Favorite